Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Inclusion Criteria:

• Have been diagnosed with:

• CLL or SLL and have received treatment with the following five classes oftherapy: Chemotherapy, anti-cluster of differentiation (anti-cd) 20 antibody,covalent Bruton's tyrosine kinase (BTK) inhibitor, B-cell lymphoma-2 (BCL-2)inhibitor, and phosphatidylinositol 3-kinase (PI3K) inhibitor

• MCL that has been previously treated with a covalent BTK inhibitor

• Richter's Transformation (RT) with previous Richter's directed-therapy

• Waldenstrom macroglobulinemia (WM), previously treated with chemotherapy,anti-CD20 antibody and a covalent BTK inhibitor

• Are not eligible for an ongoing pirtobrutinib clinical trial

Exclusion Criteria:

• Inadequate organ function

• Significant cardiovascular disease

• History of allogenic or autologous stem cell transplant (SCT) or chimeric antigenreceptor modified Tcell (CAR-T) therapy within 60 days

• Tested positive for human immunodeficiency syndrome (HIV) or known active hepatitisB or C virus or cytomegalovirus (CMV) infection

• Active, uncontrolled autoimmune cytopenia

• Clinically significant active malabsorption syndrome

• Participants requiring therapeutic anticoagulation with warfarin or another vitaminK antagonist